Living Cell Technologies Limited
LCT starts DIABECELL® Phase IIb trial in Argentina
22 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has begun patient recruitment in Argentina for a Phase IIb
trial of DIABECELL®.
The trial is designed to demonstrate the clinical benefits of DIABECELL in unstable type 1 diabetes. Twenty patients
will receive two implants of 10,000 IEQ/kg (islet equivalents per kilogram of body weight), with the second implant
occurring 12 weeks after the first. This is the dose which was shown to be most clinically effective in reducing HbA1c,
insulin dose and unaware hypoglycaemic events in the interim analysis of the Phase I/IIa trial in Argentina, announced
The principal investigator of the Phase IIb trial is Dr Adrián Abalovich of Hospital Eva Perón in San Martín, Buenos
“We are using an ‘adaptive trial design’ for our pivotal studies and so the data generated in this 20 patient trial will
likely form the foundation data for our registration package,” said Dr Andrea Grant, Chief Executive, LCT. “We remain on
track to meet our goal of completing clinical trials of DIABECELL by 2015 and having a product commercially available by
DIABECELL is a breakthrough treatment for people with unstable type 1 diabetes and is the first islet transplant
treatment that does not require ongoing administration of debilitating immunosuppression drugs. DIABECELL is owned by
the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory both have a 50%
– Ends –
For further information: www.lctglobal.com
Diabetes is usually treated with insulin replacement. A serious and potentially fatal complication associated with
intensive insulin replacement therapy is unaware hypoglycaemia. Episodes of unaware hypoglycaemia occur when, without
associated symptoms or warning, blood glucose levels drop suddenly. Some patients require significant time and resources
from specialist healthcare professionals and have a poor prognosis: lower quality of life, more micro vascular and
pregnancy complications and shortened life expectancy.
Treatment with DIABECELL® involves transplanting pig pancreatic islet cells into a patient’s abdomen to boost insulin
production and help regulate blood glucose levels. The cells are encapsulated with IMMUPEL™ to prevent the immune system
rejecting them as foreign. This proprietary technology ensures the cells can deliver their beneficial effects without
the patient requiring immunosuppressant drugs.
DIABECELL is owned by the joint venture company Diatranz Otsuka Limited, in which LCT and Otsuka Pharmaceutical Factory
both have a 50% interest.
For a summary of DIABECELL’s clinical trial programme please see the DIABECELL clinical trial update on LCT’s website www.lctglobal.com
or DIABECELL clinical trial update
About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet
clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need
for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially
those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially
fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and in Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz
Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP
into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both
LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson’s
disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain
tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New